JPM Brand Name


Generic Name





FUNZOL is indicated in the following conditions:

Acute or recurrent vaginal candidiasis.

Mucosal cadidiasis: Including oropharyngeal, esophageal, and non-invasive bronchopulmonary infections; candiduria; and in mucocutaneous and chronic oral atrophic candidiasis (denture sore mouth). Normal hosts and patients with compromised immune function may be treated with FUNZOL.

Systemic candidiasis, including candidemia, disseminated candidiasis and other invasive candidal infections: These include infections of the peritoneum, endocardium and pulmonary and urinary tracts. FUNZOL may also be used in the treatment of candidal infections in patients with malignancy, in intensive care units patients, or patients receiving cytotoxic or immunosuppressive therapy.

Cryptococcosis: Including cryptococcal meningitis and infections of other sites (e.g. pulmonary, cutaneous). Normal host and patients with acquired immune deficiency syndrome (AIDS), organ transplants or other causes of immunosuppression may be treated. FUNZOL can be used as maintenance therapy to prevent relapse of cryptococcal disease in patients with AIDS.